Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 in Relapsed/Refractory Advanced Tumors
NCT06558513Phase 2Completed
- Sponsor
- Evopoint Biosciences
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of igermetostat in advanced cancer, non-Hodgkin lymphoma (NHL), sponsored by Evopoint Biosciences. Started Aug 2021; status: completed.
02
Drugs
igermetostat
03
Conditions
advanced cancernon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06558513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558513.